Antibiotic Mechanisms of Action — Classification

Knowing an antibiotic's class tells you its mechanism, spectrum, and which side effects to expect — NCLEX tests whether you can connect those dots, not just memorize drug names.

Antibiotics are classified by how they kill or inhibit bacteria. The major mechanisms map to cellular targets. Cell wall synthesis inhibitors (penicillins, cephalosporins, carbapenems, vancomycin) are bactericidal. Penicillins, cephalosporins, and carbapenems inhibit transpeptidase (penicillin-binding proteins), blocking peptidoglycan cross-linking; vancomycin binds D-Ala-D-Ala on peptidoglycan precursors, preventing both transglycosylation and transpeptidation. Protein synthesis inhibitors target the ribosome: 30S inhibitors (aminoglycosides, tetracyclines) and 50S inhibitors (macrolides, clindamycin, linezolid). Aminoglycosides are bactericidal; most other protein synthesis inhibitors are bacteriostatic. DNA synthesis inhibitors include fluoroquinolones (block DNA gyrase/topoisomerase IV, bactericidal) and metronidazole (damages DNA in anaerobes). Folic acid synthesis inhibitors (sulfonamides, trimethoprim) block sequential steps in folate production — trimethoprim-sulfamethoxazole exploits this dual blockade. Spectrum matters: narrow-spectrum drugs target specific organisms (e.g., vancomycin for gram-positive); broad-spectrum drugs (carbapenems, fluoroquinolones) cover wider ranges but increase superinfection risk, including C. difficile. The bactericidal versus bacteriostatic distinction matters most in immunocompromised patients, where static drugs may not suffice. Key class-linked adverse effects: aminoglycosides → ototoxicity/nephrotoxicity; fluoroquinolones → tendon rupture, QT prolongation; vancomycin → red man syndrome (infusion rate-related); sulfonamides → photosensitivity, Stevens-Johnson syndrome. Nursing priority: obtain culture and sensitivity specimens BEFORE administering the first antibiotic dose.

Key Distinctions

Don't confuse bactericidal (kills bacteria — needed for severe or immunocompromised infections) with bacteriostatic (inhibits growth — depends on the immune system to finish the job). Students mix up 30S versus 50S ribosomal targets: aminoglycosides and tetracyclines hit 30S; macrolides, clindamycin, and linezolid hit 50S. Broad-spectrum is not better — it increases C. difficile and superinfection risk. Don't confuse time-dependent killing (beta-lactams — schedule doses to keep levels above MIC) with concentration-dependent killing (aminoglycosides — efficacy depends on high peak levels, hence once-daily dosing).

Clinical Pearl

"Cidal kills, static stalls." For immunocompromised patients, you want cidal drugs — their immune system can't finish what a static drug started.